Transglutaminase inhibition ameliorates experimental diabetic nephropathy

Kidney International

Volumn 76, Issue 4, 2009, Pages 383-394

  Huang, Linghong ^a   Haylor, John L ^a   Hau, Zoe ^a   Jones, Richard A ^b   Vickers, Melissa E ^a   Wagner, Bart ^c   Griffin, Martin ^d   Saint, Robert E ^b   Coutts, Ian G C ^b   El Nahas, A Meguid ^a   Johnson, Timothy S ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^c Northern General Hospital   (United Kingdom)

^d ASTON UNIVERSITY   (United Kingdom)

Author keywords

Collagen; Crosslink; Diabetic nephropathy; Extracellular matrix; Renal scarring; Transglutaminase

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; CREATININE; ENZYME INHIBITOR; NTU 281; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; UNCLASSIFIED DRUG;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; ENZYME INHIBITION; GLOMERULOSCLEROSIS; KIDNEY FUNCTION; MALE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

ANIMALS; COLLAGEN; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FIBROBLASTS; GLOMERULAR MESANGIUM; KIDNEY TUBULES; MALE; RATS; RATS, WISTAR; STREPTOZOCIN; TRANSGLUTAMINASES; TREATMENT OUTCOME;

EID: 68249108415     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.230     Document Type: Article

References (39)

1. Parving HH. Diabetic nephropathy: prevention and treatment. Kidney Int 2001; 60: 2041-2055.
2. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002; 346: 1145-1151.
3. Lameire N. Diabetes and diabetic nephropathy - a worldwide problem. Acta Diabetol 2004; 41 (Suppl 1): S3-S5.
4. Mosher DF. Cross-linking of fibronectin to collagenous proteins. Mol Cell Biochem 1984; 58: 63-68.
5. Kleman JP, Aeschlimann D, Paulsson M et al. Transglutaminase- catalyzed cross-linking of fibrils of collagen V/XI in A204 rhabdomyosarcoma cells. Biochemistry 1995; 34: 13768-13775.
6. Martinez J, Rich E, Barsigian C. Transglutaminase-mediated cross-linking of fibrinogen by human umbilical vein endothelial cells. J Biol Chem 1989; 264: 20502-20508.
7. Kaartinen MT, Pirhonen A, Linnala-Kankkunen A et al. Cross-linking of osteopontin by tissue transglutaminase increases its collagen binding properties. J Biol Chem 1999; 274: 1729-1735.
8. Aeschlimann D, Paulsson M. Cross-linking of laminin-nidogen complexes by tissue transglutaminase. A novel mechanism for basement membrane stabilization. J Biol Chem 1991; 266: 15308-15317.
9. Fisher M, Huang L, Hau Z et al. Over-Expression of Tissue Transglutaminase (tTg) in Proximal Tubular Epithelial (PTEC) Cells Affects ECM Accumulation In Vitro, in Renal Association: Belfast, Northern Ireland, UK, 2005, p 246.
10. Johnson TS, Skill NJ, El Nahas AM et al. Transglutaminase transcription and antigen translocation in experimental renal scarring. J Am Soc Nephrol 1999; 10: 2146-2157.
11. Gross SR, Balklava Z, Griffin M. Importance of tissue transglutaminase in repair of extracellular matrices and cell death of dermal fibroblasts after exposure to a solarium ultraviolet A source. J Invest Dermatol 2003; 121: 412-423.
12. Fisher M, Jones RA, Huang L et al. Modulation of tissue transglutaminase in tubular epithelial cells alters extracellular matrix levels: a potential mechanism of tissue scarring. Matrix Biol 2009; 28: 20-31.
13. Skill NJ, Griffin M, El Nahas AM et al. Increases in renal epsilon-(gammaglutamyl)-lysine crosslinks result from compartment-specific changes in tissue transglutaminase in early experimental diabetic nephropathy: pathologic implications. Lab Invest 2001; 81: 705-716.
14. El Nahas AM, Abo-Zenah H, Skill NJ et al. Elevated epsilon-(gammaglutamyl)lysine in human diabetic nephropathy results from increased expression and cellular release of tissue transglutaminase. Nephron Clin Pract 2004; 97: c108-c117.
15. Skill NJ, Johnson TS, Coutts IG et al. Inhibition of transglutaminase activity reduces extracellular matrix accumulation induced by high glucose levels in proximal tubular epithelial cells. J Biol Chem 2004; 279: 47754-47762.
16. Fisher M, Jones R, Griffin M et al. Primary Tubular Epithelial Cells Isolated From The Tissue Transglutaminase Knockout Mouse Deposit Less Extracellular Matrix Than Wild Type Cells, in Renal Associate: Harrogate, UK, 2006, p 393.
17. Bower G, Brown DM, Steffes MW et al. Studies of the glomerular mesangium and the juxtaglomerular apparatus in the genetically diabetic mouse. Lab Invest 1980; 43: 333-341.
18. Steffes MW, Buchwald H, Wigness BD et al. Diabetic nephropathy in the uninephrectomized dog: microscopic lesions after one year. Kidney Int 1982; 21: 721-724.
19. Essawy M, Soylemezoglu O, Muchaneta-Kubara EC et al. Myofibroblasts and the progression of diabetic nephropathy. Nephrol Dial Transplant 1997; 12: 43-50.
20. Goumenos DS, Tsamandas AC, Oldroyd S et al. Transforming growth factor-beta(1) and myofibroblasts: a potential pathway towards renal scarring in human glomerular disease. Nephron 2001; 87: 240-248.
21. Wolf R, Lo Schiavo A, Lombardi ML et al. The in vitro effect of hydroxychloroquine on skin morphology and transglutaminase. Int J Dermatol 1997; 36: 704-707.
22. Harrison CA, Gossiel F, Bullock AJ et al. Investigation of keratinocyte regulation of collagen I synthesis by dermal fibroblasts in a simple in vitro model. Br J Dermatol 2006; 154: 401-410.
23. Griffin M, Mongeot A, Collighan R et al.: Synthesis of potent water-soluble tissue transglutaminase inhibitors. Bioorg Med Chem Lett 2008; 18: 5559-5562.
24. Kojima S, Nara K, Rifkin DB. Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells. J Cell Biol 1993; 121: 439-448.
25. Nunes I, Gleizes PE, Metz CN et al. Latent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta. J Cell Biol 1997; 136: 1151-1163.
26. Norman JT, Orphanides C, Garcia P et al. Hypoxia-induced changes in extracellular matrix metabolism in renal cells. Exp Nephrol 1999; 7: 463-469.
27. Zeisberg M, Strutz F, Muller GA. Role of fibroblast activation in inducing interstitial fibrosis. J Nephrol 2000; 13 (Suppl 3): S111-S120.
28. Desmouliere A, Gabbiani G. Myofibroblast differentiation during fibrosis. Exp Nephrol 1995; 3: 134-139.
29. Badid C, Mounier N, Costa AM et al. Role of myofibroblasts during normal tissue repair and excessive scarring: interest of their assessment in nephropathies. Histol Histopathol 2000; 15: 269-280.
30. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004; 15: 1-12.
31. Zeisberg M, Kalluri R. The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med 2004; 82: 175-181.
32. Desmouliere A, Geinoz A, Gabbiani F et al. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993; 122: 103-111.
33. Johnson TS, El-Koraie AF, Skill NJ et al. Tissue transglutaminase and the progression of human renal scarring. J Am Soc Nephrol 2003; 14: 2052-2062.
34. Johnson TS, Hau Z, Fisher M et al. Transglutaminase Inhibition Reduce Renal Scarring by up to 92% in the Rat 5/6th Subtotal Nephrectomy (SNx) Model, in Renal Association: Aberdeen, Scotland, UK, 2004, p 6.
35. Yang B, Johnson TS, Thomas GL et al. A shift in the Bax/Bcl-2 balance may activate caspase-3 and modulate apoptosis in experimental glomerulonephritis. Kidney Int 2002; 62: 1301-1313.
36. Douthwaite JA, Johnson TS, Haylor JL et al. Effects of transforming growth factor-beta1 on renal extracellular matrix components and their regulating proteins. J Am Soc Nephrol 1999; 10: 2109-2119.
37. Vuorio T, Makela JK, Kahari VM et al. Coordinated regulation of type I and type III collagen production and mRNA levels of pro alpha 1(I) and pro alpha 2(I) collagen in cultured morphea fibroblasts. Arch Dermatol Res 1987; 279: 154-160.
38. Virolainen P, Perala M, Vuorio E et al. Expression of matrix genes during incorporation of cancellous bone allografts and autografts. Clin Orthop Relat Res 1995; 317: 263-272.
39. Kurkinen M, Condon MR, Blumberg B et al. Extensive homology between the carboxyl-terminal peptides of mouse alpha 1(IV) and alpha 2(IV) collagen. J Biol Chem 1987; 262: 8496-8499.